Tempus AI (NASDAQ:TEM) Given New $95.00 Price Target at Guggenheim

Tempus AI (NASDAQ:TEM) had its target price boosted by Guggenheim from $80.00 to $95.00 in a report released on Friday, MarketBeat Ratings reports. Guggenheim currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on the company. BTIG Research lifted their target price on Tempus AI from $75.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, August 20th. HC Wainwright raised their price objective on shares of Tempus AI from $90.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $70.00 target price on shares of Tempus AI in a research note on Friday, August 8th. Morgan Stanley increased their target price on shares of Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, August 12th. Finally, Piper Sandler restated a “neutral” rating on shares of Tempus AI in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.83.

Tempus AI Stock Up 1.5%

Shares of NASDAQ TEM opened at $78.48 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. The business’s 50 day moving average is $72.65 and its two-hundred day moving average is $62.07. Tempus AI has a 52-week low of $31.36 and a 52-week high of $97.79. The firm has a market cap of $13.63 billion, a price-to-earnings ratio of -65.95 and a beta of 5.07.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $314.64 million during the quarter, compared to analysts’ expectations of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The company’s revenue was up 89.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. Research analysts predict that Tempus AI will post -6.15 EPS for the current year.

Insider Buying and Selling

In other news, COO Ryan Fukushima sold 17,460 shares of Tempus AI stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $1,303,389.00. Following the completion of the sale, the chief operating officer directly owned 839,180 shares of the company’s stock, valued at approximately $62,644,787. The trade was a 2.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 332,500 shares of the business’s stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $74.10, for a total transaction of $24,638,250.00. Following the transaction, the chief executive officer owned 9,207,533 shares of the company’s stock, valued at approximately $682,278,195.30. The trade was a 3.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 601,787 shares of company stock valued at $42,492,268 over the last ninety days. 26.27% of the stock is currently owned by corporate insiders.

Institutional Trading of Tempus AI

A number of institutional investors have recently bought and sold shares of the business. Pathway Capital Management LP purchased a new position in shares of Tempus AI in the 1st quarter valued at about $8,576,000. SeaCrest Wealth Management LLC purchased a new position in Tempus AI in the first quarter valued at approximately $535,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Tempus AI by 31.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company’s stock worth $205,284,000 after purchasing an additional 1,016,384 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Tempus AI by 92.6% during the first quarter. Massachusetts Financial Services Co. MA now owns 578,890 shares of the company’s stock worth $27,926,000 after purchasing an additional 278,311 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Tempus AI during the 1st quarter worth approximately $1,019,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.